JP2022530044A - 腫瘍ワクチン接種方法 - Google Patents

腫瘍ワクチン接種方法 Download PDF

Info

Publication number
JP2022530044A
JP2022530044A JP2021562977A JP2021562977A JP2022530044A JP 2022530044 A JP2022530044 A JP 2022530044A JP 2021562977 A JP2021562977 A JP 2021562977A JP 2021562977 A JP2021562977 A JP 2021562977A JP 2022530044 A JP2022530044 A JP 2022530044A
Authority
JP
Japan
Prior art keywords
tumor
composition
antigen
vaccination
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021562977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530044A5 (https=
Inventor
ハンス マンティング，エリック
カウア シン，サトウィンダー
ソマンダス，ヴィノッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mendus BV
Original Assignee
DCPrime BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NL2019/050451 external-priority patent/WO2020017962A1/en
Application filed by DCPrime BV filed Critical DCPrime BV
Publication of JP2022530044A publication Critical patent/JP2022530044A/ja
Publication of JP2022530044A5 publication Critical patent/JP2022530044A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2021562977A 2019-04-25 2020-04-24 腫瘍ワクチン接種方法 Pending JP2022530044A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19170999.7 2019-04-25
EP19170999 2019-04-25
NLPCT/NL2019/050451 2019-07-16
PCT/NL2019/050451 WO2020017962A1 (en) 2018-07-16 2019-07-16 A combination product for use in tumor vaccination.
US202062961554P 2020-01-15 2020-01-15
US62/961,554 2020-01-15
PCT/IB2020/053898 WO2020217226A1 (en) 2019-04-25 2020-04-24 Methods of tumor vaccination

Publications (2)

Publication Number Publication Date
JP2022530044A true JP2022530044A (ja) 2022-06-27
JP2022530044A5 JP2022530044A5 (https=) 2023-04-28

Family

ID=72941340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562977A Pending JP2022530044A (ja) 2019-04-25 2020-04-24 腫瘍ワクチン接種方法

Country Status (6)

Country Link
US (2) US11052144B2 (https=)
EP (1) EP3958894A1 (https=)
JP (1) JP2022530044A (https=)
AU (1) AU2020264083A1 (https=)
CA (1) CA3133410A1 (https=)
WO (1) WO2020217226A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
GB201919316D0 (en) * 2019-12-24 2020-02-05 Queens Univ Of Belfast Polymeric nanoparticles for enhanced cancer treatment
CN115916963A (zh) 2020-03-27 2023-04-04 门德斯有限公司 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
EP4171617A1 (en) 2020-06-30 2023-05-03 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
CA3196677A1 (en) * 2020-11-05 2022-05-12 Erik Hans MANTING Use of tumor-independent antigens in immunotherapies
JP2024506249A (ja) * 2021-01-22 2024-02-13 メンドゥス・ベスローテン・フェンノートシャップ 腫瘍ワクチン接種の方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5667786A (en) 1995-06-07 1997-09-16 Novavax, Inc. Method for treating tumors with a toxin
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
US6398748B1 (en) 1999-03-16 2002-06-04 Robert B. Wilson Splint bandage and method
AU7116800A (en) 1999-09-09 2001-04-10 American Express Travel Related Services Company, Inc. System and method for authenticating a web page
WO2001049317A2 (en) 2000-01-05 2001-07-12 Aventis Pasteur Limited Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
US7118740B1 (en) * 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
PT1346059E (pt) 2000-11-29 2012-06-01 Pci Biotech As Internalização fotoquímica para distribuição de moléculas no citosol
EP1339862B1 (en) 2000-11-29 2014-01-08 PCI Biotech AS Photochemical internalization for virus-mediated molecule delivery into the cytosol
CA2439111A1 (en) 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
US20040057935A1 (en) 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
JP2006232761A (ja) 2005-02-25 2006-09-07 Osaka Univ 制癌剤
AU2006260240B2 (en) 2005-06-21 2012-03-15 The Research Foundation For Microbial Diseases Of Osaka University Therapeutic agent for cancer
US8476419B2 (en) 2007-09-14 2013-07-02 Vrije Universiteit Brussel Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
WO2009127988A1 (en) 2008-04-16 2009-10-22 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
WO2009019320A2 (en) 2008-05-19 2009-02-12 Dcprime B.V. Method for inducing and accelerating cells
GB0914286D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Method
CN103179952B (zh) 2010-09-02 2015-06-03 斯克里普斯研究学院 基于纳米颗粒的肿瘤靶向药物递送
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
NL2009102C2 (en) 2012-07-02 2014-01-06 Dcprime B V Method for dc-loading.
EP2743344A1 (en) 2012-12-11 2014-06-18 DCPrime B.V. Therapeutic cancer vaccines derived from a novel dendritic cell line
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
US9974848B2 (en) * 2013-11-14 2018-05-22 Duke University Tetanus toxoid and CCL3 improve DC vaccines
BR112019001115A2 (pt) 2016-07-21 2019-06-25 Vac4All Pte Ltd proteínas de biofusão como vacinas anti-malária
WO2020017962A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUZZI, S. ET AL., THERAPY, vol. 1, no. 1, JPN6024015066, 2004, pages 61 - 66, ISSN: 0005468646 *
JURINCIC-WINKLER, C.D. ET AL., ANTICANCER RES, vol. 16, JPN6024015065, 1996, pages 2105 - 2110, ISSN: 0005468645 *

Also Published As

Publication number Publication date
WO2020217226A1 (en) 2020-10-29
US11052144B2 (en) 2021-07-06
EP3958894A1 (en) 2022-03-02
AU2020264083A1 (en) 2021-12-02
US20200390876A1 (en) 2020-12-17
CA3133410A1 (en) 2020-10-29
US20210401961A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
US11071778B2 (en) Combination product for use in tumor vaccination
US11052144B2 (en) Methods of tumor vaccination
JP6903120B2 (ja) アルファウイルスワクチン接種のための組成物及び方法
US12528839B2 (en) Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
CN103415620B (zh) 诱导针对EGFRvIII的免疫应答的方法和组合物
CN1680451A (zh) 包含hpv抗原和应激蛋白或者其表达载体的组合物激发的抗hpv抗原免疫应答
CN120939216A (zh) 抗hpv和hpv相关的疾病的新疫苗
JP2022130623A (ja) がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
KR20150036191A (ko) OspA의 돌연변이체 단편 및 이에 관련된 방법 및 용도
TW202206598A (zh) 對抗ＳＡＲＳ－ＣｏＶ－２之疫苗及其製品
JP2019013229A (ja) 異種ポリペプチドを含むＣｙａＡベースのキメラタンパク質及び免疫応答の誘導におけるその使用
AU2016354590A1 (en) Lipids as synthetic vectors to enhance antigen processing and presentation
CN107286244B (zh) 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
CA3196460A1 (en) Chimeric antigen comprising the extracellular domain of pd-l1
WO2025246436A1 (en) Circular rna-based therapeutic vaccine for treating hpv positive cancer
KR102654464B1 (ko) 레오바이러스 기반 신규한 백신플랫폼 및 이의 용도
CN121518519A (zh) 多价猪圆环病毒疫苗
CN121513182A (zh) 一种基于蛋白笼-mRNA技术的炭疽－鼠疫二联疫苗及其制备方法与用途
TW202506174A (zh) 一種針對ＭＩＣＡ／Ｂ靶點的ｍＲＮＡ腫瘤疫苗
WO2016168110A2 (en) Targeted cytosolic delivery of antigenic compounds
CN114269792A (zh) 稳定的嵌合合成蛋白及其治疗用途
CN117120617A (zh) 新型核酸分子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230420

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240423

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241126